Trial · NCT06382987
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Primary | Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib or apremilast | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants treated with deucravacitinib with a change in Physician's Global Assessment (PGA) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants treated with deucravacitinib with a change in Dermatology Life Quality Index (DLQI) from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants achieving a Dermatology Life Quality Index (DLQI) score of ≤5 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 75 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve a Psoriasis Area Severity Index (PASI) response of 90 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤5 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤3 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve a National Psoriasis Foundation (NPF) Acceptable Body Surface Area response from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve an absolute scalp-specific Physician's Global Assessment (ss-PGA) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve an absolute Physician's Global Assessment-Fingernail (PGA-F) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years | |
| Secondary | Number of participants who achieve an absolute Palmoplantar Physician's Global Assessment (pp-PGA) of 0/1 from baseline to follow-up | 1 month, 3 months, 6 months and every 6 months up to 5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06382987/registered